ANNUAL REPORT 2017



We believe in a world

without blindness

no matter who you are or how old you may be.

OUR PURPOSE

How QEI helps to save sight

SUSTAINABLE FUNDING

All profits generated from the South Bank Day Hospita are invested back into the work of QEIF.

CLINICAL CARE & TREATMENT

0

We save the sight of patients every day when they see their Doctor in the QEI Clinic, involving them in cutting edge research and teaching.

Ì

 (\mathfrak{S})

Ø

Ġ

DONATIONS

Donations, Appeals, Bequests and Events together with individual and corporate supporters help fund QEIF's work. HOW QEI HELPS TO SAVE SIGHT

œ۰

S..

80

D

Ø

RESEARCH

We are saving the sight of future generations via our Research and Clinical Trials.



FUTURE TREATMENT & CURES

We are saving the sight of future generations as our Research and Education leads to new treatments and cures.



EDUCATION

Saving sight for tomorrow, we educate Registrars, Fellows, Eye Care Workers and Students.

INTRODUCTION From Chairman, Mark Sheridan, and CEO, Mark Radford

As we come to the end of another year, we continued to be inspired by the patients we have met, and the stories they tell. It is these stories that drive the work we do at Queensland Eye Institute – the work of educating the current and next generations of Clinicians and Optometrists; of conducting research to better understand and treat eye conditions, to provide the best clinical care we possibly can, and ultimately save sight.

During this past year, our Researchers and Clinicians have been active in a number of important research projects and clinical trials have focused on different aspects of eye disease and its treatment. Our emphasis on innovative and applied ideas has led to important collaborations with other teams within Australia and around the world.

The QEI Foundation Board defines our purpose and strategy, as well as overseeing corporate governance and risk, ensuring every dollar received is put to best possible use. Our Directors give their time and expertise to ensure the success of the Foundation. In 2017, we welcomed Professor Jeff Dunn AO, who is Research Leader of Social and Behavioural Science at Cancer Council Queensland (CCQ) and was previously CEO of CCQ for over 15 years. We would like to thank our fellow Board members Anthony Rafter, Jemma Elder and Jeff Dunn, for their unstinting advice and support.

We thank our team of Clinicians, Researchers, Volunteers and all our staff who strive to make a difference, to fulfil our purpose to eliminate preventable blindness in the community.

Lastly, but most importantly, we want to express our gratitude to all our donors and supporters who help us financially with their donations, as well as with their time and moral support. In particular, we acknowledge the Sylvia and Charles Viertel Charitable Foundation, its Chairman, George Curphey, and his fellow trustees for their long-term support.

We hope you find our 2017 Annual Report informative. We would welcome any suggestions you may have to help us fulfil our purpose. Together we will Save Sight!

Mark Sheridan CHAIRMAN

Mark Radford EXECUTIVE DIRECTOR AND CEO

OUR HISTORY

96

QEI is Queensland's largest independent academic research institute



UQ Chair of Ophthalmology established at the Princess Alexandra Hospital with the generous support of Charles Viertel OBE, Optical Prescription Spectacle Makers, the Royal Australian College of Ophthalmologists, Lions International and Perpetual Trustees. Lawrence Hirst appointed, as the inaugural Chair.

Australian Foundation for the Prevention of Blindness (Queensland Division) name changed to Prevent Blindness Foundation (PBF).

> QEI officially opened at the Mater Hospital with Professor Lawrence Hirst as its first CEO. The realisation of a dream shared by many people.

2010

Professor Lawrence Hirst relinquished his role as CEO to concentrate on his clinical work. Professor Mark Radford appointed as new CEO of PBF and QEI.

Sylvia & Charles Viertel Charitable Foundation awarded PBF a special grant to redevelop 140 Melbourne Street, South Brisbane to be PBF's future home and to establish South Bank Day Hospital. PBF name changes to Queensland Eye Institute Foundation (QEIF).

2014

QEI Clinic opens in South Brisbane and QEIF acquires Dr Denis Stark's Visual Electro-Diagnostic and Imaging Centre.

QEIF celebrates its 50th Anniversary whilst QEI celebrates its 10th anniversary.

Today

QEI is Queensland's largest independent academic research institute devoted to eye related health and diseases and works every day to save sight and prevent blindness. Our state of the art facilities in South Brisbane include the QEI Clinic, South Bank Day Hospital, Queensland Electro-Diagnostic and Imaging Centre, medical research and microsurgical teaching laboratories, medical library, auditorium and the home of OEIF. All of this is the result of the efforts of many people who had the strategic vision and drive to succeed, but, in particular, the support of the Sylvia & Charles Viertel Charitable Foundation, has been crucial.

BOARD OF DIRECTORS



Mark Sheridan

Mark is a Partner with leading Brisbane accountants Hanrick Curran. He has a Bachelor of Commerce (Honours) and is a Fellow, Chartered Accountants

Australia and New Zealand. He is also a Member of the Australian Institute of Company Directors and the Australian Institute of Managers and Leaders. Mark was appointed a Director of the Queensland Eye Institute Foundation in 2003, and Chairman in 2011. He is also Chairman of South Bank Medical Group, which operates day surgery facilities to support QEI's long-term objectives.



Professor Mark Radford EXECUTIVE DIRECTOR AND CEO

Mark has been Executive Director and CEO of the Queensland Eye Institute Foundation since 2010. He has a Doctor of Medicine from Nagasaki University,

Japan and a PhD from Flinders University of South Australia. Mark is a Fellow of both the Australian Institute of Company Directors and the Institute of Managers and Leaders, and an Honorary Fellow of the Royal Australian and New Zealand College of Ophthalmologists.



Professor Jeff Dunn, AO DIRECTOR

Jeff is Research Leader of Social and Behavioural Science at Cancer Council Queensland (CCQ)'s Cancer Research Centre and was previously

CEO of CCQ for over 15 years. He is Professor and Chair of Social and Behavioural Science at the University of Southern Queensland (USQ). He currently holds Professorial appointments with the University of Southern Queensland and the Griffith University School of Medicine. Jeff was appointed an Officer in the Order of Australia in June 2014 for distinguished service to medical administration through leadership roles with cancer control organisations, and to the promotion of innovative and integrated cancer care programs. Jeff is a Graduate of the Australian Institute of Company Directors (GAICD) and holds a PhD from The University of Queensland.



Jemma Elder DIRECTOR

Jemma Elder is a Managing Director with Publicis Australia, an entity of the Publicis Groupe one of the world's largest media and communications

agency networks. Her remit spans the management of businesses in commercial partnership with Publicis including Personalised Plates Queensland (Department of Transport and Main Roads), KiwiPlates (New Zealand Transport Agency) and Qantas Corporate SME Sales. Jemma brings extensive business, sales and marketing experience having previously worked in senior positions with ASX listed companies. Jemma holds a Bachelor of Business and Grad Certificate Applied Finance. She is a member of the AICD and sits on Advisory Committees that foster entrepreneurial learning and enterprise development.



Judge Anthony Rafter DIRECTOR

Anthony is currently a District Court Judge in Queensland. He was admitted as a Barrister of the Supreme Court of Queensland in 1985, and then

Senior Counsel in 2003. Prior to joining the Queensland Eye Institute Foundation Board in 2012, Anthony was Chairperson for the Nursing Tribunal and a Board member of Legal Aid Queensland.



Kelly Langdon COMPANY SECRETARY

Kelly has been associated with the Queensland Eye Institute since 2004 in a general management capacity. Her qualifications include a Bachelor

of Human Resource Management and Economics. Kelly was appointed as Company Secretary of the Foundation in 2015 and enjoys the variety and scope of work together with the opportunity to bring her strong commercial acumen to the not for profit sector.

IMPACT AND OUTCOMES



QEDIC

Patients Seen - 290 patients, 88 were children.

Clinical Trials

Eight trials undertaken.





IMPACT AND OUTCOMES

Research

19 Researchers in total, four were students.



Ten publications and eight presentations.



Education

Grand Rounds - 26% increase. 253 attendees in 2016, 320 in 2017.

Optometry Nights - 20% increase. 300 attendees in 2016, 360 in 2017.

Wetlabs - 253% increase. 13 attendees in 2016, 46 in 2017.



R

Optometry Students 87 students in 2017.

Website

Website Sessions - 161% increase. 11,106 in 2016, 28,984 in 2017.

2017 28,984 2017 28,984 2017 +73% 2016

x 87 STUDENTS

Online Donations

A 73% increase on 2016.



ARVO



It was an Australian first for the Asia-Pacific Association for Research in Vision and Ophthalmology (ARVO) meeting held in Brisbane. February 2017 saw over 800 delegates including senior ophthalmologists, researchers and industry leaders from around the world joining together at the Brisbane Convention and Exhibition Centre. The theme was 'Bridging disciplines and disparities: Connecting eye research with health outcomes'.

The Hon Jackie Trad Deputy Premier, Minister for Transport and Minister for Infrastructure and Planning QLD (above with QEI's CEO, Mark Radford) opened the meeting.

GG "Bringing together the calibre of speakers, researchers, clinicians, regulators and global corporate leaders and investors was a real coup for ARVO and Brisbane." QEI's CEO, Professor Mark Radford, who was the Chair of the Meeting and instrumental in bringing the meeting to Australia said: "Bringing together the calibre of speakers, researchers, clinicians, regulators and global corporate leaders and investors was a real coup for ARVO and Brisbane. My co-chairs, Professor Justine Smith (Flinders University) and Professor Peter McCluskey (Save Sight Institute, Sydney University), Scientific Programme Chairs Professors Stephanie Watson and John Grigg, and the ARVO Asia committee did an excellent job and worked tirelessly to provide a meeting to add real value to delegates."



NOEL'S LEGACY

over 40 million cells preserved for the Australian research industry

Married for over 50 years and long-standing QEI supporters, Noel and Pam had decided to donate their eyes to research. Noel had a hereditary condition called Retinitis Pigmentosa (known as RP with the effect of tunnel vision) and lost his sight completely in 1987. Pam meanwhile has glaucoma and a long history of extremely low vision, after being born with no irises and she has also had cataracts removed.

Noel sadly passed away in October 2017 which meant on the day of his passing, his heartfelt wish to donate his eyes for research could now be fulfilled with a prompt response to ensure Noel's eyes would be in best condition for study.

Professor Damien Harkin, Senior Scientist at QEI and Queensland University of Technology, had met with Noel to discuss his bequest. *"He had hoped to donate his corneas for clinical use, but unfortunately he was not eligible due to having lung cancer. The next best option was to donate his eyes to research, so I discussed with Noel and Pam how this would work and the type of information that could be gained from studying his eyes."*

On the day of Noel's passing, QEI's Community Relations Manager, Jane Dodds, who had become a frequent visitor to the couple received a call from Pam with the sad news of Noel's passing. Jane recalls, *"It was naturally with mixed emotions I received the news. Pam was clearly saddened by Noel's passing, but her commitment to ensuring that his eyes were collected promptly was really evident."*

> Having retrieved Noel's eyes within a few hours of his passing enabled Professor Harkin to preserve the retinal tissue so it would be suitable for future study by electron



Noel's cells living on



microscopy. Electron microscopy would enable scientists to study in very fine detail the effect of RP on Noel's retinas. But it was not just the retina that was of interest; other areas of the eye, including the cornea, would also be able to provide important information.

"While RP affects the retina, the genetic changes that cause this condition will be present throughout other cells in Noel's body," Professor Harkin explained. "So by growing cells from Noel's corneas we could obtain an additional source of cellular material for genetic analyses and other studies." These other studies include the potential use of Noel's cells for developing genecorrection techniques that might one day be used to treat patients like Noel before they become blind.

Within one month of Noel's passing, Professor Harkin had grown over 40 million of Noel's corneal cells, stored frozen in liquid nitrogen, in readiness for distribution to the Australian ophthalmic research community.

QEI's capability to help people fulfill their desire to donate eye tissue, and ensure that QEI's researchers and other groups in Australia can then utilise the tissue in their studies is all part of QEI's purpose - to Save Sight.

U

CLINICAL CARE & TREATMENT

Anna Blake, Clinical Services Manager

QEI Clinic Overview

The QEI Clinic continues to go from strength to strength with over 17,000 patient appointments in 2017. This is over 300 patients a week seeing QEI's eight Doctors who provide medical and surgical management of routine and complex eye disorders with a full range of ophthalmic services. Saving the sight of patients every day is our ultimate goal together with involving them in research and teaching.

We are delighted to have welcomed Dr Elias Kehdi to the QEI Clinic as an eye surgeon with a special interest in children's eye conditions.

Cordelia Dermatology has expanded and continues to provide many patients with the unique facility to have MOHS surgery for malignant skin tumours with Dermatologist, Dr Karyn Lun, followed by surgical closure by our Oculoplastic specialist, Dr Tai Smith.

The QEI Clinic and South Bank Day Hospital partnership has continued to strengthen with the referral of Surgery Connect patients. The public patients are assessed at the QEI Clinic before their procedures are performed at the South Bank Day Hospital. Follow up care then occurs in the QEI Clinic. The QEI Clinic also continues to receive paediatric cases via the contract negotiated with the Lady Cilento Children's Hospital. Dr Sharma in collaboration with the QEI Clinic has also worked on building a practice at the Lady Bjelke Petersen Community Hospital in Kingaroy leading to a monthly clinic and theatre list.

Placements for optometry, orthoptist and medical students increased with specialised training for Assistant Surgeons being undertaken, whilst full training on the Privacy Act was undertaken by all QEI Clinic staff.

The close working and collaborative relationship of the QEI Clinic Doctors with the QEI Foundation Research Team continues, with more ideas for projects being identified through the needs of patients. These projects will lead to new treatments and cures.

Retinal Eye Disease First For QEI

Patients with low vision due to retinal disease will be one step nearer to a clearer diagnosis with a first for Queensland with QEI having the State's only Maia Microperimetry machine, which analyses retinal function.

QEI Clinic's Dr Abhishek Sharma says, "This new machine, which has previously only been available in research centres in Melbourne and Sydney, combines retinal imaging, retinal sensitivity mapping and fixation analysis in one examination and is a powerful tool to detect, describe and follow up pathologies affecting the macular area – the most sensitive part of the retina."

The great advantage of the Maia machine is its ability to record and control a patient's fixation activity while measuring their visual field. This eliminates errors caused by fixation losses.

Zambia Mission Group

Over 400 pairs of glasses were distributed to the villagers of Ndola in Zambia via the QEI Clinic. The glasses were kindly donated by patients, particularly those who had cataract surgery and no longer needed them. For many of the villagers a pair of glasses transforms their lives, restoring their ability to read, do tailoring work or other tasks to enable them to seek employment. The team at the QEI Clinic cleaned, bagged and recorded prescriptions of the glasses for the 12,500km trip to the Zambia Mission Group in Ndola.







Saving the sight of future generations via our Research and Education is leading to new treatments and cures.

Projects included:

- Investigation of tissue-engineered cells-biomaterial constructs, based on proteins isolated from silk developed at QEI for cellular therapies aimed at treating ocular surface disorders, regenerating corneal endothelium, and as substrates for retinal cell transplantation. These activities were supported in part by two National Health & Medical Research Council (NHMRC) on-going grants.
- Professor Damien Harkin and his group have progressed research looking at the potential use of mesenchymal stromal cells for the restoration of the cornea.
- Professor Traian Chirila, in collaboration with scientists from The University of Queensland, studied the effect of the surface of polymeric substrates on the attachment and growth of corneal cells.
- Dr Shuko Suzuki and Professor Chirila established a method for enzymatic crosslinking of silk fibroin with a view of improving its properties as a substrate for cellular growth.

- Associate Professor Nigel Barnett's research continued on the processes leading to disease of the retina and the optic nerve, including the development of an antioxidative strategy against retinal degeneration.
- Our researchers, together with Dr Tai Smith, QEI's oculoplastic surgeon, have started to work on a new treatment for floppy eyelid syndrome, with patent protection filed in Australia and United States.

QEI's researchers have published 14 articles/book chapters in scientific publications, and attended a number of national and international conferences. During the year, we hosted an internship student from France, who carried out research under Dr Suzuki's supervision.

National and international collaborative work was undertaken with: the University of Würzburg, Germany; the University of Marseille, France; Gunze Co., Kyoto, Japan; National Agriculture & Food Research Organization - Tsukuba, Japan; Queensland University of Technology, The University of Queensland, and the University of Western Australia.

Publications 2017

 Santander-Borrego M., Taran E., Shadforth A.M.A., Whittaker A.K., Chirila T.V. and Blakey I.: Hydrogels with lotus leaf topography: Investigating surface properties and cell adhesion. Langmuir 33(2): 485-493, 2017.

(2) Shadforth A.M.A., Suzuki S., Theodoropoulos C., Richardson N.A., Chirila T.V. and Harkin D.G.: A Bruch's membrane substitute fabricated from slik fibroin supports the function of retinal pigment epithelial cells in vitro. J. Tissue Eng. Regen. Med., 11(6): 1915-1924, 2017.

(3) Chirila T.V., Suzuki S. and Delcroix O.: Enzymatic crosslinking of Bombyx mori silk fibroin biomaterials: An investigation of the gel point by dynamic rheology. Biomater. Tissue Technol., 2017, 1(1). DOI: 10.15761/BT1.1000103. [4 pages]

(4) Chirila T.V., Suzuki S. and Papolla C.: A comparative investigation of Bombyx mori silk fibroin hydrogels generated by chemical and enzymatic cross-linking. Biotechnol. Appl. Biochem., 64(6): 771-781, 2017.

(5) Chirila T.V.: Oxygen permeability of silk fibroin membranes: A critical review and personal perspective. Biomater. Tissue Technol., 2017, 1(2). DOI: 10.15761/BTT.1000109. [5 pages]

(6) Santander-Borrego M., Chirila T.V., Shadforth A.M.A., Whittaker A.K. and Blakey I.: Effect of changes in the surface chemistry and topography of poly(2-hydroxyethyl methacrylate) on the in vitro attachment of human corneal epithelial cells. J. Bioact. Compat. Polym., in press; DOI: 10.1177/0883911517744572.

(7) Smith T.M., Suzuki S., Cronin B.G., Haghighatpanah M., Petcu E.B., Philippa C.J. and Chirila T.V.: Photochemically induced crosslinking of tarsal collagen as a treatment for eyelid laxity: assessing potentiality in animal tissue. Ophthal. Plast. Reconstr. Surg., in press; DOI: 10.1097/ IOP.0000000000000063. (8) Bobba S., Di Girolamo N., Mills R.A., Daniell M., Chan E., Harkin D.G., Cronin B.G., Crawford G.J., McGhee C.N. and Watson, S.: Nature and incidence of severe limbal stem cell deficiency in Australia and New Zealand. Clin. Exper. Ophthalmol., 45(2): 174-181, 2017.

(9) Yang C.H., Albietz J., Harkin D.G., Kimlin M.G. and Schmid K.L.: Impact of oral vitamin D supplementation on the ocular surface in people with dry eye and/or low serum vitamin D. Cont. Lens Anterior Eye, in press; DOI: 10.1016/j.clae.2017.09.007.

(10) Harkin D.G., Dunphy S.E., Shadforth A.M.A., Dawson R.A., Walshe J. and Zakaria N.: Mounting of biomaterials for use in ophthalmic cell therapies. Cell Transplantation, in press.

(11) Natoli R., Fernando N., Jiao H., Racic T., Madigan M., Barnett N.L., Chu-Tan J.A., Valter K., Provis J. and Rutar M.: Retinal macrophages synthesize C3 and activate complement in AMD and in models of focal retinal degeneration. Invest. Ophthalmol. Vis. Sci., 58: 2977-2990, 2017.

(12) Quek H., Luff J., Cheung K., Kozlov S., Gatei M., Lee C.S., Bellingham M.C., Noakes P.G., Lim Y.C., Barnett N.L., Dingwall S., Wolvetang E., Mashimo T., Roberts T.L. and Lavin M.F.: Rats with a missense mutation in Atm display neuroinflammation and neurodegeneration subsequent to accumulation of cytosolic DNA following unrepaired DNA damage. J. Leukocyte Biol., 101: 927-947, 2017.

(13) Quek H., Luff J., Cheung K., Kozlov S., Gatei M., Lee C.S., Bellingham M.C., Noakes P.G., Lim Y.C., Barnett N.L., Dingwall S., Wolvetang E., Mashimo T., Roberts T.L. and Lavin M.F. A rat model of ataxia-telangiectasia: evidence for a neurodegenerative phenotype. Hum. Mol. Genet., 26: 109-123, 2017.

(14) Thakur S.S., Ward M.S., Popat A., Flemming N.B., Parat M.O., Barnett N.L. and Parekh H.S. Stably engineered nanobubbles and ultrasound - An effective platform for enhanced macromolecular delivery to representative cells of the retina. PLoS One 12: e0178305, 2017.

Flinders University

South Bank Day Hospital (SBDH) embarked on a new partnership aimed to benefit both patients and doctors. Vitreoretinal lymphoma is a rare cancer that occurs inside the eye. This cancer threatens the eyesight, but even more seriously, it is often associated with brain lymphoma that may be fatal.

Because vitreoretinal lymphoma is rare – affecting less than one person in 100,000 – there is little information to guide treating doctors and inform patients and their families. Through a partnership with Flinders University, SBDH will be establishing an international vitreoretinal lymphoma registry to guide medical care, and develop education materials to provide information to patients.

Facebook and Instagram



Sadly, there is no cure for people affected by age-related macular degeneration (AMD) and those with advanced degeneration are considered legally blind. Scientists Dr Audra Shadforth and Professor Damien Harkin here at the Queensland Eye institute are working on a cellular therapy treatment to repair vision loss caused by AMD. The ultimate goal is to one day restore full functionality of the retina through a routine implant procedure similar to how we currently treat cataracts. Just imagine...

Find out more about the regenerative medicine here: http://www.gei.org.au/page/home/latest-news/amd-research/

And please donate today. www.cei.org.au/donate



One in seven Australian over 50 have evidence of Macular Degeneration. The most advance...



....

Learn More











10



Ð

Now b prot. Mark

0.0

Of Star

in Funders He

Overview

There are five main focus areas for the QEI Education program to achieve its goal of saving sight for tomorrow.

- The QEI rotation through The University of Queensland Medical School is one of the most popular amongst medical students for its hands-on and practical approach.
- Increased numbers of Queensland University of Technology optometry students have been coming through the QEI Clinic as a part of the practical component to their optometry degree. Again, placements at the Queensland Eye Institute are very popular amongst students and we now receive requests from interstate including Deakin University and also orthoptic students from Melbourne University to obtain placements.
- Our Facebook Ophthalmology for Medical Students page continues to be very popular. This free service provides a quick, easy, and simple way for medical students to learn important facts about ophthalmology.
- Our Optometry Education series continues to build momentum. Events are now so popular that each is held twice to accommodate the 200 plus attendees. These events are free of charge and open to clinical, retail, and research-based optometrists all around Queensland. In the future we hope to be teleconferencing these across the internet to broaden their reach.
- The Grand Rounds held in conjunction with RANZCO have seen a 21 per cent increase in attendance this year. Doctors from rural and remote areas are able to access this valuable service via a live broadcast enabling them to have the same level of education and professional development as Doctors from inner city areas.

Optometry Education Series

As part of QEI's purpose to save sight, QEI provides a range of Education programs including a valuable Optometry Education Series with over 350 attendees in 2017. QEI brings together professionals with a common aim to gain new knowledge in vision sciences and to play a key role in reducing vision loss.



💿 L-R. Dr Abhishek Sharma with Dr Tai Smith and Dr Brendan Cronin.



Jason and his boys

For the 2017 Christmas Appeal we highlighted the story of Jason, a young father of four who has been blind in one eye since birth, has congenital glaucoma, and now has just 10% sight left in his other eye. Tragically, he could wake up any day completely blind.

Glaucoma has also struck other members of his young family. His four year-old son Zac is a carrier with high eye pressures and Troy has vision issues, both of which could lead to blindness.

"My biggest fear every day is not being able to see our children grow up, get married and to see our grandchildren."



"I'd have been blind in 2015 if it hadn't have been for QEI"

Jason says the research QEI undertakes has a profound impact on his life and the lives of many others each and every day.

"My clinical care and QEI's scientific research has saved my sight, allowing me to maintain my independence which means so much to me."



Schoolgirls team up to sell slime!

QEI received a special donation from four good school friends who attend the Genesis Christian College in the Moreton Bay region of Queensland.

Rachel, Poppy, Lilly and Claudia got together to make homemade slime, which they called Rachipilaud Slimes! Claudia's Mum is one of the Nurses at QEI and she suggested the girls donate their fundraising efforts to QEI to help save sight a wonderful effort!

Sjögren's Syndrome

The focus of QEI's March appeal was Sjögren's Syndrome, which attacks the body's moistureproducing glands such as tear and salivary glands. It causes painful dryness in the eyes and throat and for QEI patient, Wilma Puntigam, who kindly shared her story it often leaves her unable to see. *"I have to wear sunglasses inside some days, and other days the light is so crippling that I might as well be blind. Sometimes it makes everyday tasks impossible,"* she said.

Whilst it is considered a manageable condition with eye drops and mouth washes that ease the symptoms of Sjögren's, the implications can be debilitating on a person's social life and ability to work. The world's first clinical trial, which started at QEI and has now moved to Brisbane's Wesley Hospital, has seen 30 Sjögren's Syndrome sufferers given stem cells from a placenta to modify the abnormal activity of their immune system and determine if the treatment helps to enable the regeneration of these moisture-producing glands.



South Bank Day Hospital

The South Bank Day Hospital (operated by South Bank Medical Group) provides a unique partnership with the QEI Clinic enabling patients to have their clinical diagnosis, procedure, treatment and care all under one roof at 140 Melbourne Street, South Brisbane. With over 1000 patients a year, all profits generated by the hospital are invested back into the work of the QEI Foundation.

Lady Bjelke-Petersen Community Hospital

The Kingaroy-based Lady Bjelke-Petersen Hospital is also operated by South Bank Medical Group. Services provided include: ophthalmic, general surgery, orthopaedic, gynaecology and dental together with a Palliative Care Unit, Wound Care Clinic and an afterhours palliative care programme.

OUR TEAM

Board of Directors

Mark Sheridan CHAIRMAN

Professor Mark Radford EXECUTIVE DIRECTOR AND CEO

Professor Jeff Dunn DIRECTOR

Jemma Elder DIRECTOR

Anthony Rafter DIRECTOR

Kelly Langdon COMPANY SECRETARY

Clinical Faculty

Dr Mark Chiang GLAUCOMA, CATARACT AND DISEASES OF THE RETINA

Dr Brendan Cronin CORNEA AND ANTERIOR SEGMENT

Dr Elias Kehdi PAEDIATRICS

Associate Professor Anthony Kwan RETINAL DISEASES

Dr Anthony Pane NEURO-OPHTHALMOLOGY

Dr Abhishek Sharma MEDICAL AND SURGICAL RETINAL DISEASES Dr Tai Smith OCULOPLASTIC, LACRIMAL AND ORBIT SURGERY

Professor Ravi Thomas GLAUCOMA AND CLINICAL EPIDEMIOLOGY

Research Faculty

Professor Traian Chirila SENIOR SCIENTIST

Associate Professor Nigel Barnett SENIOR SCIENTIST

Professor Damien Harkin VISITING SENIOR SCIENTIST

Professor Lawrence Hirst RESEARCH SCIENTIST

Dr Allison Sutherland MANAGER OF CLINICAL RESEARCH SERVICES

Dr Shuko Suzuki SENIOR RESEARCH OFFICER

Dr Jinchun (Fiona) Li RESEARCH OFFICER

Dr Audra Shadforth RESEARCH OFFICER

Dr Jennifer Young RESEARCH OFFICER

Honorary Research Faculty

Professor Murray Baker UNIVERSITY OF WESTERN AUSTRALIA Associate Professor Idriss Blakey THE UNIVERSITY OF QUEENSLAND

Professor Paul Dalton UNIVERSITY OF WURZBURG, GERMANY

Dr Tim Dargaville QUEENSLAND UNIVERSITY OF TECHNOLOGY

Dr Katie Edwards QUEENSLAND UNIVERSITY OF TECHNOLOGY

Dr Beatrix Feigl INSTITUTE OF HEALTH & BIOMEDICAL INNOVATION (IHBI)

Professor Eugen B Petcu GRIFFITH UNIVERSITY

Associate Professor Katrina Schmid QUEENSLAND UNIVERSITY OF TECHNOLOGY

Professor Andrew Whittaker THE UNIVERSITY OF QUEENSLAND

Management Team

Kelly Langdon CHIEF OPERATING OFFICER

Anna Blake CLINICAL SERVICES MANAGER

Jane Dodds COMMUNITY RELATIONS OFFICER

Rachell Hansen PARTNERSHIPS MANAGER

Carmel Johnston EA TO THE EXECUTIVE DIRECTOR AND CEO

FINANCIAL SNAPSHOT

Extracted from the Audited Financial Statements for January 1 to December 31, 2017

Balance Sheet Comparatives

ASSETS	2017 \$	2016 \$
CURRENT ASSETS		
Cash and cash equivalents	4,394,966	5,376,614
Trade and other receivables		1,668,949
Other assets		141,028
TOTAL CURRENT ASSETS		
NON-CURRENT ASSETS		
Trade and other receivables		2,157,152
Investments in subsidiaries		47
Financial assets		
Property, plant and equipment		
Intangible assets		54,503
TOTAL NON-CURRENT ASSETS		12,432,281
TOTAL ASSETS	17,683,640	19,618,872
LIABILITIES		
Trade and other payables		5,284,017
Employee benefits		509,698
Other financial liabilities	123,049	476,925
TOTAL LIABILITIES	6,133,784	6,270,640
NET ASSETS	11,549,856	13,348,232

Income Statement Comparatives

NET COMPREHENSIVE INCOME/(LOSS)

REVENUE Sylvia & Charles Viertel Charitable Foundation Bequests and other donations Clinical cost recoveries ArvoAsia17 income Other income	2017 \$ 1,930,000	2016 \$ 2,680,000 3,680,785 2,103,113 - 386,065
TOTAL INCOME	6,332,335	8,849,963
EXPENSES		
Employee benefits expense	3,746,987	3,634,271
Depreciation and amortisation expense	1,033,818	974,415
Research costs	174,433	111,426
Occupancy costs	1,891,604	1,917,288
Administrative expenses	80,483	17,231
Fundraising expenses	198,099	56,869
Clinical costs	229,520	256,814
Grant expenses		12,300
ArvoAsia17 expenses	431,298	47,939
Other general expenses	322,188	411,934
Finance costs	22,281	22,542
TOTAL EXPENSES	8,130,711	7,463,029

1,386,934

(1,798,376)

THANK YOU From the team at QEI

The work of the Queensland Eye Institute Foundation is due to the support of so many people: our generous donors, supporters, partners, volunteers, our staff and our Board.

As always we are grateful for the moral and financial support of the Sylvia & Charles Viertel Charitable Foundation, and especially its Board of Trustees and Chairman, George Curphey.

Our success would not be possible without the unstinting support of our donors and we would like to sincerely extend our thanks. And to the many organisations that provide their assistance in numerous different ways, thank you again for your support in 2017.

And last but by no means least, thank you to our many volunteers who give up their time and expertise so generously to assist us to continue with our sight saving work.



www.qei.org.au

2 140 Melbourne St, Sth Brisbane Qld 4101

